ecteinascidin 743 has been researched along with Neoplasms in 68 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 30 (44.12) | 29.6817 |
| 2010's | 32 (47.06) | 24.3611 |
| 2020's | 6 (8.82) | 2.80 |
| Authors | Studies |
|---|---|
| Bharate, SB; Joshi, P; Vishwakarma, RA | 1 |
| Crescenzi, E; D'Incalci, M; Leonardi, A; Mellone, S; Pacifico, F; Stornaiuolo, M | 1 |
| Wang, M; Yao, ZJ; Yu, BB | 1 |
| Coussens, NP; Dexheimer, TS; Doroshow, JH; Morris, J; Silvers, T; Teicher, BA; Wright, J | 1 |
| Alvarez-Lucena, C; Boscá, L; Cascante, M; Castrillo, A; de la Rosa Medina, JV; Fariñas, M; Fernández-Moreno, MA; Foguet, C; Landauro-Vera, R; Marin, S; Mas, F; Mojena, M; Povo-Retana, A; Sánchez-García, S | 1 |
| Bauermeister, A; Branco, PC; Costa-Lotufo, LV; Gaudêncio, SP; Jimenez, PC; Rezende-Teixeira, P; Wilke, DV | 1 |
| Arizza, V; Lazzara, V; Mauro, M; Punginelli, D; Vazzana, M | 1 |
| Ray-Coquard, I | 1 |
| Biroccio, A; Leonetti, C; Pompili, L; Salvati, E | 1 |
| Guerriero, JL | 1 |
| Costa-Lotufo, LV; Jimenez, PC; Wilke, DV | 1 |
| Chin, AL; Deresinski, S; Gong, CL; Srinivas, S; Studdert, AL | 1 |
| Alfaro, V; Christinat, A; Cresta, S; Del Conte, G; Fernández-Teruel, C; Gallerani, E; Gianni, L; Iglesias, JL; Kahatt, C; Lardelli, P; Perotti, A; Sessa, C | 1 |
| Allavena, P; Bello, E; Cuevas, C; D'Incalci, M; Erba, E; Frapolli, R; Galmarini, CM; García-Fernández, LF; Porcu, L; Romano, M; Zangarini, M | 1 |
| Allavena, P; D'Incalci, M; Frapolli, R; Germano, G | 1 |
| Albella, B; Aracil, M; Bueren, JA; Gago, F; Galmarini, CM; Martínez, S; Pérez, L; Tercero, JC | 1 |
| D'Incalci, M | 1 |
| Allavena, P; D'Incalci, M; Galmarini, CM | 1 |
| Bernard, A; Dirix, L; Herremans, C; Keung, C; Khokhar, NZ; Knoblauch, R; Machiels, JP; Parekh, TV; Phelps, C; Sharma, S; Staddon, A | 1 |
| Bartsch, R; Deutschmann, C; Felberbauer, FX; Hacker, S; Haslik, W; Kornauth, C; Mader, RM; Thallinger, C | 1 |
| Bookman, M; Cohen, RB; Knoblauch, R; Li, J; Meropol, NJ; Parekh, T; Sherman, E; von Mehren, M; Weiner, LM | 1 |
| Jahn, F; Jordan, B; Jordan, K; Kegel, T; Müller-Tidow, C; Rüssel, J | 1 |
| Issels, R; Kampmann, E; Kanaar, R; Lindner, LH | 1 |
| Shah, P; Singh, IP | 1 |
| Fu, LW; Zhang, JY | 1 |
| Antony, S; Aune, GJ; Bohr, VA; Guirouilh-Barbat, J; Pommier, Y; Sordet, O; Takagi, K | 1 |
| Bailly, C | 1 |
| Alfaro, V; Chu, Q; Forouzesh, B; Gómez, J; Hidalgo, M; Jimeno, J; Lebedinsky, C; Mita, A; Mita, M; Rowinsky, EK; Schwartz, G; Zintl, P | 1 |
| Avilés, P; Bueren-Calabuig, JA; Cuevas, C; Domingo, A; Gago, F; Galmarini, CM; García-Fernández, LF; García-Hernández, V; Guillén-Navarro, MJ; Leal, JF; Moneo, V; Negri, A | 1 |
| Molinski, T | 1 |
| Alfaro, V; Chu, Q; Forouzesh, B; Lebedinsky, C; Mita, A; Nieto, A; Rowinsky, EK; Schwartz, G; Soto-Matos, A; Tolcher, AW | 1 |
| Frezza, AM; Napolitano, A; Santini, D; Schiavon, G; Tonini, G; Vincenzi, B | 1 |
| D'Incalci, M; Galmarini, CM | 1 |
| Vollmar, AM; von Schwarzenberg, K | 1 |
| Barlow, C; Florez, A; Garcia, M; Judson, I; Kaye, SB; Lebedinsky, C; Magem, M; Montes, A; Pardo, B; Salazar, R; Vidal, L | 1 |
| Blay, JY; Delaloge, S; Demetri, GD; Frontelo, P; Jiao, JJ; Le Cesne, A; Maki, RG; Misset, JL; Nieto, A; Yovine, A | 1 |
| Escargueil, AE; Galmarini, CM; Henriques, JA; Larsen, AK; Machado, MS; Ouaret, D; Poindessous, V; Rocca, CJ; Sarasin, A; Soares, DG | 1 |
| Alfaro, V; Ciruelos, E; Cortés-Funes, H; Cuadra, C; García, M; Lebedinsky, C; Majem, M; Montes, A; Pardo, B; Paz-Ares, L; Salazar, R; Soto-Matos, A | 1 |
| Dirix, LY; Jain, MM; Jiao, JJ; Manikhas, GM; Natarajan, J; Parekh, T; Park, K; Staddon, AP; Thertulien, R; Vermorken, JB; Zannikos, P | 1 |
| Basche, M; Cleere, D; Eckhardt, SG; Elsayed, YA; Eppers, S; Gore, L; Grolnic, S; Li, J; Moulder-Thompson, SL; O'Bryant, C; Rivera, E | 1 |
| Allavena, P; Mantovani, A | 1 |
| Hartley, JA; Hochhauser, D | 1 |
| Aikin, A; Balis, FM; Bayever, E; Chuk, MK; Fox, E; Whitcomb, T; Widemann, BC; Zannikos, P | 1 |
| Borbone, E; D'Angelo, D; D'Incalci, M; Esposito, F; Frapolli, R; Fusco, A; Pacelli, R; Palmieri, D; Uboldi, S | 1 |
| Chabner, BA | 1 |
| Bailly, C; Lansiaux, A | 1 |
| Taguchi, T | 1 |
| Smyth, JF | 2 |
| Anthoney, A; Beijnen, JH; Bowman, A; Gomez, J; Guzmán, C; Hanauske, A; Hoekman, K; Jimeno, J; Smyth, J; Twelves, C; Uiters, J; van Kesteren, C; Vermorken, JB; Wanders, J | 1 |
| Beijnen, JH; de Vooght, MM; Jimeno, JM; López-Lázaro, L; Mathôt, RA; Schellens, JH; van Kesteren, Ch | 1 |
| Amador, ML; Cortes-Funes, H; Hidalgo, M; Jimeno, J; Paz-Ares, L | 1 |
| D'Incalci, M; Jimeno, J | 1 |
| Izquierdo, MA; Jimeno, J; López-Martín, JA; Rinehart, K; Ruiz-Casado, A; Scheuer, PJ | 1 |
| Baruchel, S; Bernstein, M; Blaney, S; Hershon, L; Jimeno, J; Krailo, M; Lau, L; Malkin, D; Qu, W; Seibel, N; Supko, JG | 1 |
| Beijnen, JH; Beumer, JH; Bosch, TM; Hillebrand, MJ; Lopez-Lazaro, L; Rademaker-Lakhai, JM; Rosing, H; Schellens, JH | 1 |
| Hirankarn, S; Lopez-Lazaro, L; Ludwig, EA; Owen, JS; Perez-Ruixo, JJ; Soto-Matos, A; Stuyckens, K; Zannikos, P | 1 |
| Brahmer, J; Donehower, RC; Elsayed, Y; Ettinger, D; Hidalgo, M; Jimeno, A; Khan, Y; Laheru, D; Lansey, D; Messersmith, WA; Zannikos, P | 1 |
| Bayever, E; Cardoso, TM; Cheng, JD; Cohen, RB; Renshaw, FG; Schilder, RJ; Temmer, E; von Mehren, M; Yuan, Z; Zannikos, P | 1 |
| Córdoba, S; De La Torre, A; Jimeno, JM; López-Martín, JA; Molerón, R; Romero, J; Sánchez-Prieto, R; Tercero, JC; Vargas, JA; Zapata, I | 1 |
| Beijnen, JH; Brain, E; Cvitkovic, E; Guzman, C; Hillebrand, MJ; Jimeno, JM; López-Lázaro, L; Math t, RA; Misset, JL; Rosing, H; Schellens, JH; Taamma, A; van Kesteren, C | 1 |
| Brain, E; Cvitkovic, E; Guzman, C; Jimeno, JM; Lopez Lazaro, L; Misset, JL; Riofrio, M; Rosing, H; Taamma, A | 1 |
| Clark, JW; Davis, J; Demetri, G; Eder, JP; Fischman, AJ; Jimeno, J; Lynch, TJ; Ryan, DP; Seiden, MV; Supko, JG | 1 |
| Adams, J; Elliott, PJ | 1 |
| Beijnen, JH; Campbell, E; Eckhardt, SG; Guzman, C; Hidalgo, M; Jimeno, J; Kraynak, M; Lopez-Lazaro, L; Rosing, H; Rowinsky, EK; van Kesteren, C; Villalona-Calero, MA; Von Hoff, DD; Weiss, G | 1 |
| Cvetkovic, RS; Figgitt, DP; Plosker, GL | 1 |
| Albella, B; Bueren, JA; Faircloth, G; Guzmán, C; Jimeno, J; López-Lázaro, L | 1 |
28 review(s) available for ecteinascidin 743 and Neoplasms
| Article | Year |
|---|---|
Natural alkaloids as P-gp inhibitors for multidrug resistance reversal in cancer.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Products; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship | 2017 |
Enriching cancer pharmacology with drugs of marine origin.
Topics: Animals; Antineoplastic Agents; Biological Products; Clinical Trials as Topic; Cytarabine; Drug Discovery; Furans; Humans; Ketones; Neoplasms; Porifera; Trabectedin | 2020 |
Antitumoral compounds from vertebrate sister group: A review of Mediterranean ascidians.
Topics: Animals; Antineoplastic Agents; Biological Products; Depsipeptides; Humans; Mediterranean Sea; Neoplasms; Peptides, Cyclic; Trabectedin; Urochordata | 2020 |
Trabectedin mechanism of action and platinum resistance: molecular rationale.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Dioxoles; DNA; Drug Resistance, Neoplasm; Genes, BRCA1; Genes, BRCA2; Humans; Mutation; Neoplasms; Platinum; Prognosis; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2017 |
Diagnosis and treatment of ALT tumors: is Trabectedin a new therapeutic option?
Topics: Antineoplastic Agents, Alkylating; Dioxoles; Humans; Neoplasms; Telomere; Telomere Homeostasis; Tetrahydroisoquinolines; Trabectedin | 2017 |
Macrophages: The Road Less Traveled, Changing Anticancer Therapy.
Topics: Animals; Antineoplastic Agents; Humans; Macrophages; Molecular Targeted Therapy; Neoplasms; Neovascularization, Pathologic; Trabectedin; Tumor Microenvironment | 2018 |
Marine drugs for cancer: surfacing biotechnological innovations from the oceans.
Topics: Antineoplastic Agents; Aquatic Organisms; Biotechnology; Brentuximab Vedotin; Cytarabine; Drug Development; Drug Discovery; Furans; Immunoconjugates; Ketones; Neoplasms; Oceans and Seas; Trabectedin | 2018 |
Trabectedin mechanism of action: what's new?
Topics: Animals; Antineoplastic Agents, Alkylating; Dioxoles; DNA Damage; Humans; Macrophages; Neoplasms; Tetrahydroisoquinolines; Trabectedin; Tumor Microenvironment | 2013 |
Trabectedin and plitidepsin: drugs from the sea that strike the tumor microenvironment.
Topics: Animals; Antineoplastic Agents; Aquatic Organisms; Cell Death; Cell Survival; Depsipeptides; Dioxoles; Disease Progression; Humans; Molecular Targeted Therapy; Neoplasms; Peptides, Cyclic; Tetrahydroisoquinolines; Trabectedin; Tumor Microenvironment | 2014 |
Trabectedin: Supportive care strategies and safety profile.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Neoplasms; Ovarian Neoplasms; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2015 |
Hallmarks of hyperthermia in driving the future of clinical hyperthermia as targeted therapy: translation into clinical application.
Topics: Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Combined Modality Therapy; Dioxoles; DNA Repair; Humans; Hyperthermia, Induced; Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2016 |
Tetrahydroisoquinolines in therapeutics: a patent review (2010-2015).
Topics: Animals; Antineoplastic Agents, Alkylating; Central Nervous System Diseases; Dioxoles; Drug Design; Humans; Neoplasms; Patents as Topic; Tetrahydroisoquinolines; Trabectedin | 2017 |
[Advance of several types of important marine antitumor drugs].
Topics: Animals; Antineoplastic Agents; Apoptosis; Biological Products; Bryostatins; Cell Line, Tumor; Depsipeptides; Dioxoles; Disulfides; Ethers, Cyclic; Humans; Macrolides; Marine Biology; Neoplasms; Tetrahydroisoquinolines; Trabectedin; Tyrosine | 2008 |
Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Cycle; Clinical Trials as Topic; Dioxoles; DNA Adducts; DNA Damage; DNA Repair; Drug Evaluation, Preclinical; Humans; Neoplasms; Tetrahydroisoquinolines; Trabectedin; Urochordata | 2010 |
A review of trabectedin (ET-743): a unique mechanism of action.
Topics: Animals; Dioxoles; DNA; DNA Repair; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2010 |
Targeting apoptosis pathways by natural compounds in cancer: marine compounds as lead structures and chemical tools for cancer therapy.
Topics: Alkaloids; Alkanes; Animals; Anti-Bacterial Agents; Antineoplastic Agents; Apoptosis; Aquatic Organisms; Biological Products; Bryostatins; Carbamates; Cell Proliferation; Depsipeptides; Dioxoles; Drug Screening Assays, Antitumor; Humans; Lactones; Macrolides; Microtubules; Models, Chemical; Neoplasms; Phenanthrolines; Phenazines; Proteasome Endopeptidase Complex; Pyrones; Pyrroles; Quinolines; Spiro Compounds; Steroids; Tetrahydroisoquinolines; Thiazoles; Trabectedin | 2013 |
Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Chemotaxis; Clodronic Acid; Cytokines; Dioxoles; Disease Progression; Humans; Immunity, Innate; Inflammation; Liposomes; Macrophages; Mice; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Tetrahydroisoquinolines; Trabectedin; Tumor Escape; Tumor Microenvironment | 2012 |
Small molecule drugs - optimizing DNA damaging agent-based therapeutics.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Benzodiazepinones; Dioxoles; DNA; DNA Damage; Humans; Neoplasms; Nitrogen Mustard Compounds; Pyrroles; Tetrahydroisoquinolines; Trabectedin | 2012 |
Cytotoxic agents in the era of molecular targets and genomics.
Topics: Antineoplastic Agents, Alkylating; Dioxoles; Humans; Isoquinolines; Neoplasms; Pharmacogenetics; Tetrahydroisoquinolines; Trabectedin | 2002 |
Trabectedin: ET 743, ecteinascidin 743, Yondelis.
Topics: Animals; Antineoplastic Agents, Alkylating; Dioxoles; Drugs, Investigational; Humans; Isoquinolines; Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2003 |
[Development of marine-derived anti-cancer compounds].
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Depsipeptides; Dioxoles; Female; Humans; Isoquinolines; Male; Marine Biology; Mollusca; Neoplasms; Peptides; Peptides, Cyclic; Porifera; Survival Analysis; Tetrahydroisoquinolines; Trabectedin; Urochordata | 2003 |
Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Cycle; Chemistry, Pharmaceutical; Clinical Trials as Topic; Dioxoles; Female; Humans; Isoquinolines; Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2003 |
Progress in the development and acquisition of anticancer agents from marine sources.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bryostatins; Clinical Trials, Phase I as Topic; Depsipeptides; Dioxoles; Drug Screening Assays, Antitumor; Humans; Isoquinolines; Lactones; Macrolides; Marine Biology; Neoplasms; Oligopeptides; Peptides, Cyclic; Tetrahydroisoquinolines; Trabectedin | 2003 |
Preclinical and clinical results with the natural marine product ET-743.
Topics: Animals; Antineoplastic Agents, Alkylating; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dioxoles; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Isoquinolines; Neoplasms; Tetrahydroisoquinolines; Trabectedin; Urochordata | 2003 |
Progress in the clinical development of new marine-derived anticancer compounds.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chemistry, Pharmaceutical; Clinical Trials as Topic; Depsipeptides; Dioxoles; Humans; Isoquinolines; Marine Biology; Neoplasms; Peptides; Peptides, Cyclic; Tetrahydroisoquinolines; Trabectedin | 2004 |
Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Dioxoles; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Models, Statistical; Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2007 |
New agents in cancer clinical trials.
Topics: Antineoplastic Agents; Benzamides; Benzoquinones; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dioxoles; Enzyme Inhibitors; Humans; Hydroxamic Acids; Imatinib Mesylate; Isoquinolines; Lactams, Macrocyclic; Neoplasms; Piperazines; Pyrazines; Pyrimidines; Rifabutin; Stilbenes; Tetrahydrofolates; Tetrahydroisoquinolines; Trabectedin; Vorinostat | 2000 |
ET-743.
Topics: Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Dioxoles; Humans; Isoquinolines; Liver; Neoplasms; Neutropenia; Survival Analysis; Tetrahydroisoquinolines; Thrombocytopenia; Trabectedin | 2002 |
18 trial(s) available for ecteinascidin 743 and Neoplasms
| Article | Year |
|---|---|
Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dioxoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome; Young Adult | 2013 |
Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.
Topics: Adult; Antineoplastic Agents; Cytochrome P-450 CYP3A; Dioxoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Antagonism; Drug Monitoring; Drug Screening Assays, Antitumor; Drug-Related Side Effects and Adverse Reactions; Enzyme Activators; Enzyme Inhibitors; Female; Humans; Ketoconazole; Male; Metabolic Clearance Rate; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms; Rifampin; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2014 |
Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Docetaxel; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Taxoids; Tetrahydroisoquinolines; Trabectedin | 2015 |
Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies.
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Alkylating; Area Under Curve; Creatine Kinase; Dioxoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Tetrahydroisoquinolines; Trabectedin; Transaminases; Young Adult | 2009 |
Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dioxoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Feasibility Studies; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Paclitaxel; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome; Young Adult | 2010 |
Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Dioxoles; England; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Spain; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome; Young Adult | 2012 |
A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antineoplastic Agents, Alkylating; Child; Dioxoles; Female; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Rhabdomyolysis; Tetrahydroisoquinolines; Trabectedin; Young Adult | 2012 |
Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dioxoles; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Liver; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2012 |
Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Asthenia; Dioxoles; Electrocardiography; Female; Heart Rate; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Single-Blind Method; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome; Vomiting; Young Adult | 2012 |
Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Dioxoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Tetrahydroisoquinolines; Trabectedin; Young Adult | 2012 |
A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Child; Dexamethasone; Dioxoles; Female; Humans; Male; Neoplasm Recurrence, Local; Neoplasms; Recurrence; Tetrahydroisoquinolines; Time Factors; Trabectedin | 2012 |
Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Cohort Studies; Dioxoles; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Isoquinolines; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2003 |
A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Dioxoles; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Isoquinolines; Male; Maximum Tolerated Dose; Neoplasms; Salvage Therapy; Tetrahydroisoquinolines; Time Factors; Trabectedin | 2005 |
Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Deoxycytidine; Dioxoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2008 |
A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Male; Middle Aged; Neoplasms; Polyethylene Glycols; Tetrahydroisoquinolines; Trabectedin | 2008 |
Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Dioxoles; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Isoquinolines; Male; Middle Aged; Neoplasms; Neutropenia; Tetrahydroisoquinolines; Thrombocytopenia; Trabectedin | 2001 |
Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antineoplastic Agents, Alkylating; Area Under Curve; Aspartate Aminotransferases; Dioxoles; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Isoquinolines; Liver; Male; Maximum Tolerated Dose; Middle Aged; Models, Chemical; Neoplasms; Tetrahydroisoquinolines; Time Factors; Toxicity Tests; Trabectedin | 2001 |
A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antineoplastic Agents, Alkylating; Area Under Curve; Aspartate Aminotransferases; Dioxoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Isoquinolines; Liver; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Tetrahydroisoquinolines; Time Factors; Tissue Distribution; Trabectedin | 2002 |
22 other study(ies) available for ecteinascidin 743 and Neoplasms
| Article | Year |
|---|---|
Trabectedin suppresses escape from therapy-induced senescence in tumor cells by interfering with glutamine metabolism.
Topics: Amino Acid Transport System ASC; Cell Cycle Checkpoints; Cell Line, Tumor; Cellular Senescence; Glutamine; Humans; Minor Histocompatibility Antigens; Neoplasms; Neoplastic Stem Cells; Trabectedin | 2022 |
Simplified hybrids of two anticancer bistetrahydroisoquinoline alkaloids ecteinascidin 743 and cribrostatin 4 and inhibitory activity against proliferation of cancer cells.
Topics: Alkaloids; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Molecular Structure; Neoplasms; Structure-Activity Relationship; Tetrahydroisoquinolines; Trabectedin | 2022 |
Multicellular Complex Tumor Spheroid Response to DNA Repair Inhibitors in Combination with DNA-damaging Drugs.
Topics: Ataxia Telangiectasia; DNA; DNA Repair; DNA-Activated Protein Kinase; Endothelial Cells; Humans; Neoplasms; Spheroids, Cellular; Temozolomide; Topotecan; Trabectedin | 2023 |
Immunometabolic actions of trabectedin and lurbinectedin on human macrophages: relevance for their anti-tumor activity.
Topics: Humans; Lactic Acid; Macrophages; Neoplasms; Trabectedin; Tumor Microenvironment | 2023 |
Application of pharmacoeconomics to formulary management in a health system setting.
Topics: Academic Medical Centers; Clinical Trials as Topic; Cost-Benefit Analysis; Dacarbazine; Drug Approval; Drug Costs; Drug Utilization Review; Economics, Pharmaceutical; Formularies as Topic; Humans; Interdisciplinary Communication; Markov Chains; Models, Economic; Neoplasms; Pharmaceutical Services; Pharmacy and Therapeutics Committee; Trabectedin; Treatment Outcome; United States; United States Food and Drug Administration | 2019 |
Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104).
Topics: Alkaloids; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Carbolines; Cell Cycle; Cell Proliferation; Cells, Cultured; Chickens; Dioxoles; DNA Damage; DNA Repair; Flow Cytometry; Heterocyclic Compounds, 4 or More Rings; Humans; In Vitro Techniques; Mice; Mice, Inbred C57BL; Mice, Nude; Molecular Structure; Neoplasms; Tetrahydroisoquinolines; Trabectedin; Xenograft Model Antitumor Assays | 2013 |
New activities for the anti-tumor agent trabectedin: taking two birds with one stone.
Topics: Animals; Antineoplastic Agents; Dioxoles; Humans; Neoplasms; Tetrahydroisoquinolines; Trabectedin; Tumor Microenvironment | 2013 |
Inhibitory effects of marine-derived DNA-binding anti-tumour tetrahydroisoquinolines on the Fanconi anaemia pathway.
Topics: Animals; Antineoplastic Agents; Binding Sites; Carbolines; Cell Line, Tumor; Dioxoles; DNA; Dose-Response Relationship, Drug; Fanconi Anemia; Fanconi Anemia Complementation Group Proteins; Hematopoietic Stem Cells; Heterocyclic Compounds, 4 or More Rings; Humans; Mice; Mice, 129 Strain; Mice, Inbred BALB C; Mice, Transgenic; Mitomycin; Neoplasms; Signal Transduction; Tetrahydroisoquinolines; Trabectedin | 2013 |
Port-a-Cath extravasation of vesicant cytotoxics: surgical options for a rare complication of cancer chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Body Mass Index; Cisplatin; Device Removal; Dioxoles; Epirubicin; Equipment Failure; Extravasation of Diagnostic and Therapeutic Materials; Female; Humans; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Risk Factors; Surgical Flaps; Tetrahydroisoquinolines; Therapeutic Irrigation; Trabectedin; Vascular Access Devices; Young Adult | 2015 |
Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Cell Survival; Cells, Cultured; Cockayne Syndrome; Cysteine Proteinase Inhibitors; Dioxoles; DNA Damage; DNA Helicases; DNA Repair; DNA Repair Enzymes; DNA-Binding Proteins; Fibroblasts; Genetic Complementation Test; Humans; Leupeptins; Neoplasms; Phosphorylation; Poly-ADP-Ribose Binding Proteins; RNA Polymerase II; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Transcription, Genetic; von Hippel-Lindau Disease; Von Hippel-Lindau Tumor Suppressor Protein; Xeroderma Pigmentosum; Xeroderma Pigmentosum Group D Protein | 2008 |
Ready for a comeback of natural products in oncology.
Topics: Antineoplastic Agents; Biological Products; Dioxoles; Epothilones; Humans; Neoplasms; Sirolimus; Tetrahydroisoquinolines; Trabectedin | 2009 |
Molecular pharmacology and antitumor activity of Zalypsis in several human cancer cell lines.
Topics: Animals; Antibiotics, Antineoplastic; Cell Line, Tumor; Dioxoles; Drug Screening Assays, Antitumor; Humans; Mice; Mice, Nude; Neoplasms; Tetrahydroisoquinolines; Trabectedin; Xenograft Model Antitumor Assays | 2009 |
Marine natural products.
Topics: Animals; Biological Products; Clinical Trials, Phase II as Topic; Conservation of Natural Resources; Dioxoles; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Marine Biology; Mice; Mice, Nude; Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2009 |
Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells.
Topics: Antineoplastic Agents, Alkylating; Carbolines; Cell Line, Tumor; Chromatin; Cisplatin; Dioxoles; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Drug Synergism; HCT116 Cells; Heterocyclic Compounds, 4 or More Rings; HT29 Cells; Humans; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Tetrahydroisoquinolines; Trabectedin; Ultraviolet Rays | 2011 |
The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin.
Topics: Antineoplastic Agents, Alkylating; Cells, Cultured; Dioxoles; DNA; Gene Expression Regulation, Neoplastic; HEK293 Cells; HMGA Proteins; Humans; Neoplasms; Promoter Regions, Genetic; Protein Binding; Radiation Tolerance; Radiation-Sensitizing Agents; Signal Transduction; Tetrahydroisoquinolines; Trabectedin; Transcriptional Activation; Validation Studies as Topic | 2013 |
[Perspectives on the oncologist pharmacopoeia].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Dioxoles; Indoles; Isoquinolines; Neoplasms; Organoplatinum Compounds; Protease Inhibitors; Pyrazines; Pyrroles; Quinazolines; Sesquiterpenes; Tetrahydroisoquinolines; Trabectedin | 2003 |
Rationale for drug combinations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dioxoles; Humans; Isoquinolines; Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2003 |
Metabolism of trabectedin (ET-743, Yondelis) in patients with advanced cancer.
Topics: Antineoplastic Agents, Alkylating; Chromatography; Dioxoles; Feces; Glucuronides; Humans; Mass Spectrometry; Neoplasms; Polymorphism, Genetic; Tetrahydroisoquinolines; Trabectedin | 2007 |
In vitro radiosensitisation by trabectedin in human cancer cell lines.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Dioxoles; DNA Repair; Flow Cytometry; HeLa Cells; HT29 Cells; Humans; Neoplasms; Radiation-Sensitizing Agents; Tetrahydroisoquinolines; Trabectedin; Tumor Cells, Cultured | 2008 |
Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Agents, Alkylating; Area Under Curve; Aspartate Aminotransferases; Dioxoles; Dose-Response Relationship, Drug; Female; Humans; Isoquinolines; Liver; Male; Middle Aged; Models, Chemical; Neoplasms; Neutropenia; Tetrahydroisoquinolines; Thrombocytopenia; Time Factors; Trabectedin | 2000 |
Science and serendipity in cancer research.
Topics: Antineoplastic Agents, Alkylating; Dioxoles; Human Genome Project; Humans; Isoquinolines; Neoplasms; Research; Research Support as Topic; Science; Tetrahydroisoquinolines; Trabectedin | 2001 |
In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors. comparison with the clinical results.
Topics: Antineoplastic Agents; Bone Marrow Diseases; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Depsipeptides; Dioxoles; Doxorubicin; Drug Screening Assays, Antitumor; Hematopoietic Stem Cells; Humans; Inhibitory Concentration 50; Isoquinolines; Neoplasms; Peptides, Cyclic; Tetrahydroisoquinolines; Trabectedin; Tumor Cells, Cultured | 2002 |